Two Sigma Securities LLC Lowers Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Two Sigma Securities LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 82.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,811 shares of the medical equipment provider's stock after selling 13,378 shares during the quarter. Two Sigma Securities LLC's holdings in Zimmer Biomet were worth $297,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at approximately $25,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at about $39,000. OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $40,000. SRS Capital Advisors Inc. boosted its stake in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after buying an additional 285 shares during the last quarter. Finally, Atala Financial Inc purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $51,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JMP Securities restated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Trading Up 0.3 %

Shares of Zimmer Biomet stock traded up $0.26 during trading hours on Friday, hitting $102.08. The company's stock had a trading volume of 3,275,103 shares, compared to its average volume of 1,668,216. The firm has a fifty day moving average of $105.64 and a 200-day moving average of $106.53. The stock has a market cap of $20.20 billion, a price-to-earnings ratio of 22.94, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a twelve month low of $93.10 and a twelve month high of $123.96. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business posted $2.20 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. Zimmer Biomet's payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.